45
EVIA Life Sciences raises $5.5M in first Reg D offering from Tokyo base
Company raise · Raising · Tokyo, Japan · Form D filed 2026-11-02 · Follow EVIA Life Sciences Inc. →
EVIA Life Sciences, a Delaware biotech corporation based in Tokyo, is raising $5.5M under Regulation D exemption 6(b). The company has sold $700K to one investor so far and is seeking $4.8M more.
Note: Entity location listed as 'TOKYO, M0' (likely 'TOKYO, Japan' with malformed state code); issuer is Delaware-incorporated but Japan-based, which may affect service provider jurisdiction and regulatory requirements.
First raise on EDGARother
How this compares
- No earlier fund launch by this sponsor appears on EDGAR.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
People on the filing
| Kosuke Takishima | Executive Officer |
| Joshua Raphael Schwab | Director |
| Michael Kim | Director |
| Takahiro Ochiya | Director |
Signed by Kosuke Takishima, Chief Executive Officer.
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans.